Chronic Hep B Treatment | VEMLIDY® (tenofovir alafenamide) VEMLIDY® is a prescription medication used to treat chronic hepatitis B virus in adults with stable liver disease See Important Safety Information and important warnings on this site
VEMLIDY® Co-pay Savings Program | VEMLIDY® (tenofovir alafenamide) Do you need help understanding your health insurance and Gilead medication costs for VEMLIDY®? Learn more today about co-pay support and access See Important Safety Information and important warnings on this site
ISI - VEMLIDY WHAT IS VEMLIDY? VEMLIDY is a prescription medicine used to treat chronic (long-lasting) hepatitis B virus (HBV) in adults with stable (compensated) liver disease VEMLIDY may lower the amount of HBV in your body VEMLIDY may improve the condition of your liver
VEMLIDY® FAQs | VEMLIDY® (tenofovir alafenamide) VEMLIDY is a prescription medicine used to treat chronic (long-lasting) hepatitis B virus (HBV) in adults with stable (compensated) liver disease VEMLIDY may lower the amount of HBV in your body
IMPORTANT FACTS - VEMLIDY VEMLIDY is a prescription medicine used to treat chronic (long-lasting) hepatitis B virus (HBV) in adults and children 6 years of age and older who weigh at least 55 pounds (25 kg) with stable (compensated) liver disease
Support Path® Program | VEMLIDY® (tenofovir alafenamide) Do you need help understanding your health insurance and Gilead medication costs for VEMLIDY®? Discover support and access options See Important Safety Information and important warnings on this site
Safety with VEMLIDY® | VEMLIDY® (tenofovir alafenamide) VEMLIDY is a prescription medicine used to treat chronic (long-lasting) hepatitis B virus (HBV) in adults with stable (compensated) liver disease VEMLIDY may lower the amount of HBV in your body VEMLIDY may improve the condition of your liver
Results with VEMLIDY® | VEMLIDY® (tenofovir alafenamide) VEMLIDY trial participants were studied through 8 years (Week 384) Trial 108 (425 patients) and Trial 110 (873 patients) studied the efficacy and safety of VEMLIDY (25 mg daily) for patients with chronic hepatitis B with stable liver disease compared to another medicine called tenofovir disoproxil fumarate (TDF, 300 mg daily) Between these 2 trials, patients were either on VEMLIDY (866